RATIONALE: Understanding the mechanisms that regulate trafficking of human cardiac stem cells (hCSCs) may lead to development of new therapeutic approaches for the failing heart. OBJECTIVE: We tested whether the motility of hCSCs in immunosuppressed infarcted animals is controlled by the guidance system that involves the interaction of Eph receptors with ephrin ligands. METHODS AND RESULTS: Within the cardiac niches, cardiomyocytes expressed preferentially the ephrin A1 ligand, whereas hCSCs possessed the EphA2 receptor. Treatment of hCSCs with ephrin A1 resulted in the rapid internalization of the ephrin A1-EphA2 complex, posttranslational modifications of Src kinases, and morphological changes consistent with the acquisition of a motile cell phenotype. Ephrin A1 enhanced the motility of hCSCs in vitro, and their migration in vivo following acute myocardial infarction. At 2 weeks after infarction, the volume of the regenerated myocardium was 2-fold larger in animals injected with ephrin A1-activated hCSCs than in animals receiving control hCSCs; this difference was dictated by a greater number of newly formed cardiomyocytes and coronary vessels. The increased recovery in myocardial mass with ephrin A1-treated hCSCs was characterized by further restoration of cardiac function and by a reduction in arrhythmic events. CONCLUSIONS: Ephrin A1 promotes the motility of EphA2-positive hCSCs, facilitates their migration to the area of damage, and enhances cardiac repair. Thus, in situ stimulation of resident hCSCs with ephrin A1 or their ex vivo activation before myocardial delivery improves cell targeting to sites of injury, possibly providing a novel strategy for the management of the diseased heart.
RATIONALE: Understanding the mechanisms that regulate trafficking of human cardiac stem cells (hCSCs) may lead to development of new therapeutic approaches for the failing heart. OBJECTIVE: We tested whether the motility of hCSCs in immunosuppressed infarcted animals is controlled by the guidance system that involves the interaction of Eph receptors with ephrin ligands. METHODS AND RESULTS: Within the cardiac niches, cardiomyocytes expressed preferentially the ephrin A1 ligand, whereas hCSCs possessed the EphA2 receptor. Treatment of hCSCs with ephrin A1 resulted in the rapid internalization of the ephrin A1-EphA2 complex, posttranslational modifications of Src kinases, and morphological changes consistent with the acquisition of a motile cell phenotype. Ephrin A1 enhanced the motility of hCSCs in vitro, and their migration in vivo following acute myocardial infarction. At 2 weeks after infarction, the volume of the regenerated myocardium was 2-fold larger in animals injected with ephrin A1-activated hCSCs than in animals receiving control hCSCs; this difference was dictated by a greater number of newly formed cardiomyocytes and coronary vessels. The increased recovery in myocardial mass with ephrin A1-treated hCSCs was characterized by further restoration of cardiac function and by a reduction in arrhythmic events. CONCLUSIONS:Ephrin A1 promotes the motility of EphA2-positive hCSCs, facilitates their migration to the area of damage, and enhances cardiac repair. Thus, in situ stimulation of resident hCSCs with ephrin A1 or their ex vivo activation before myocardial delivery improves cell targeting to sites of injury, possibly providing a novel strategy for the management of the diseased heart.
Authors: Khalid Salaita; Pradeep M Nair; Rebecca S Petit; Richard M Neve; Debopriya Das; Joe W Gray; Jay T Groves Journal: Science Date: 2010-03-12 Impact factor: 47.728
Authors: Claudia Bearzi; Annarosa Leri; Francesco Lo Monaco; Marcello Rota; Arantxa Gonzalez; Toru Hosoda; Martino Pepe; Khaled Qanud; Caroline Ojaimi; Silvana Bardelli; Domenico D'Amario; David A D'Alessandro; Robert E Michler; Stefanie Dimmeler; Andreas M Zeiher; Konrad Urbanek; Thomas H Hintze; Jan Kajstura; Piero Anversa Journal: Proc Natl Acad Sci U S A Date: 2009-08-27 Impact factor: 11.205
Authors: Hui Miao; Da-Qiang Li; Amitava Mukherjee; Hong Guo; Aaron Petty; Jennifer Cutter; James P Basilion; John Sedor; Jiong Wu; David Danielpour; Andrew E Sloan; Mark L Cohen; Bingcheng Wang Journal: Cancer Cell Date: 2009-07-07 Impact factor: 31.743
Authors: Olaf Bergmann; Ratan D Bhardwaj; Samuel Bernard; Sofia Zdunek; Fanie Barnabé-Heider; Stuart Walsh; Joel Zupicich; Kanar Alkass; Bruce A Buchholz; Henrik Druid; Stefan Jovinge; Jonas Frisén Journal: Science Date: 2009-04-03 Impact factor: 47.728
Authors: Maria Genander; Michael M Halford; Nan-Jie Xu; Malin Eriksson; Zuoren Yu; Zhaozhu Qiu; Anna Martling; Gedas Greicius; Sonal Thakar; Timothy Catchpole; Michael J Chumley; Sofia Zdunek; Chenguang Wang; Torbjörn Holm; Stephen P Goff; Sven Pettersson; Richard G Pestell; Mark Henkemeyer; Jonas Frisén Journal: Cell Date: 2009-11-13 Impact factor: 41.582
Authors: Kazu Kikuchi; Jennifer E Holdway; Andreas A Werdich; Ryan M Anderson; Yi Fang; Gregory F Egnaczyk; Todd Evans; Calum A Macrae; Didier Y R Stainier; Kenneth D Poss Journal: Nature Date: 2010-03-25 Impact factor: 49.962
Authors: Konstantinos E Hatzistergos; Dieter Saur; Barbara Seidler; Wayne Balkan; Matthew Breton; Krystalenia Valasaki; Lauro M Takeuchi; Ana Marie Landin; Aisha Khan; Joshua M Hare Journal: Circ Res Date: 2016-08-01 Impact factor: 17.367
Authors: Steven Daniel Funk; Arif Yurdagul; Patrick Albert; James G Traylor; Long Jin; Jin Chen; A Wayne Orr Journal: Arterioscler Thromb Vasc Biol Date: 2012-01-12 Impact factor: 8.311